Physician profile
Danilo Calderon
NPI 1093730772
$2,837.08
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $846 · 2020: $205 · 2021: $762 · 2022: $978 · 2023: $46.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $399.54 | 2019-2023 | Vraylar |
| Glaxosmithkline, LLC. | $340.96 | 2019-2022 | |
| Amgen INC. | $250.38 | 2019-2022 | |
| Lilly USA, LLC | $226.67 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $189.86 | 2019-2022 | |
| Novo Nordisk INC | $162.32 | 2019-2022 | |
| Astellas Pharma US INC | $141.59 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $134.18 | 2019 | |
| Amarin Pharma, INC. | $129.79 | 2019-2022 | |
| Pfizer INC. | $123.28 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.53 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $103.97 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $100.81 | 2019-2022 | |
| Almatica Pharma LLC | $96.35 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.22 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $64.45 | 2021-2022 | |
| Esperion Therapeutics, INC. | $41.06 | 2021 | |
| Vifor Pharma, INC. | $26.79 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.86 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $20.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.79 | 2021 | |
| Daiichi Sankyo INC. | $16.63 | 2021 | |
| Boston Scientific Corporation | $15.87 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danilo Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.